Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Can-Fite BioPharma Ltd. Sponsored ADR +6.37%

Can-Fite BioPharma Ltd. Sponsored ADR

CANF

2.38

+6.37%

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the pancreatic cancer indication of Can-Fite.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via